IP Library Granted Patent US 9,616,039
Granted Patent B2
US 9,616,039 · App. 15/171,910 · Granted Apr 11, 2017

Treatment of NAFLD and NASH

Inventors: Brian Roberts (Los Altos, CA); Xueyan Wang (Foster City, CA); Yun-Jung Choi (Fremont, CA); David Karpf (Mountain View, CA); Robert Martin (San Ramon, CA); Charles McWherter (Oakland, CA)
Assignee: CYMABAY THERAPEUTICS, INC.
A61K31/192A61K9/0053A61K31/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,616,039
App. No.
15/171,910
Granted
Apr 11, 2017
Kind
B2
Abstract

Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.

Claims (12)

1. A method of treating a disease that is non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) by orally administering a therapeutically effective amount of (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)-acetic acid (MBX-8025) or a salt thereof.

2. The method of claim 1 where the daily dose of MBX-8025 or a salt thereof (when calculated as the free acid) is 20-200 mg/day.

3. The method of claim 2 where the daily dose of MBX-8025 or a salt thereof (when calculated as the free acid) is 50-100 mg/day.

4. The method of claim 1 where the MBX-8025 or a salt thereof is administered once/day.

5. A method of treating NAFLD by orally administering a therapeutically effective amount of MBX-8025 or a salt thereof.

6. The method of claim 5 where the daily dose of MBX-8025 or a salt thereof (when calculated as the free acid) is 20-200 mg/day.

7. The method of claim 6 where the daily dose of MBX-8025 or a salt thereof (when calculated as the free acid) is 50-100 mg/day.

8. The method of claim 5 where the MBX-8025 or a salt thereof is administered once/day.

9. A method of treating NASH by orally administering a therapeutically effective amount of MBX-8025 or a salt thereof.

10. The method of claim 9 where the daily dose of MBX-8025 or a salt thereof (when calculated as the free acid) is 20-200 mg/day.

11. The method of claim 10 where the daily dose of MBX-8025 or a salt thereof (when calculated as the free acid) is 50-100 mg/day.

12. The method of claim 9 where the MBX-8025 or a salt thereof is administered once/day.

Assignments (1)
RELEASE OF SECURITY INTEREST Recorded Oct 3, 2024
From: ABW CYCLOPS SPV LP
To: CYMABAY THERAPEUTICS, INC.
Reel/Frame 069833/0155 →
Continuity (3)
Continuation 14684100 · Apr 10, 2015
Provisional Application 61978335 · Apr 11, 2014
Related Publication 20160324812A1 · Nov 10, 2016